首页> 外文会议>International Conference on Biomedical Engineering in Vietnam >A Case Study on Expression of Single-Chain Variable Fragment of Anti-HER2 Antibody by Using Recombinant Baculovirus in Silkworms
【24h】

A Case Study on Expression of Single-Chain Variable Fragment of Anti-HER2 Antibody by Using Recombinant Baculovirus in Silkworms

机译:用蚕蚕病毒使用重组杆状病病毒单链可变片段表达的案例研究

获取原文

摘要

HER2 (Epidermal Human Growth Factor Receptor), is one of receptors in the epidermal growth factor receptor family. The overexpression of HER2 was determined in 25% to 35% of patients which were positive with breast cancer and in some of different cancers such as ovary cancer, uterus cancer... Due to this characteristic, HER2 has become an effective molecular marker for pre-diagnosis as well as a strike target for immune therapeutically treatment. Currently, there are different types of monoclonal antibodies (mAbs) specific to HER2 which produced based on recombinant DNA technology. These recombinant mAbs are bringing many benefits for diagnosis and making more effective in the treatment of breast cancer. In this research, the pair of primers (BacHER2F/BacHER2R) was designed to amplify antiHER2 antibody (antiHER2 Ab) fragment (Single-chain variable fragment, scFv) which had been moved into a cloning vector and confirmed by sequencing. An expression vector containing this fragment (vector Bacmid/AntiHER2) has been constructed and transfected into a cultured Sf9 insect cells to produce recombinant baculovirus (r-BV). The virus then infected to silkworm Bombyx mori and the recombinant antiHER2 Ab (r-antiHER2 Ab) was expressed successfully. The expressed protein was confirmed by Western blot analysis. We obtained r-antiHER2 Ab using Ni-NTA affinity chromatography. Our result verified that we received purified r-antiHER2 Ab with 95% purity, which can be used for next experiments.
机译:Her2(表皮人生长因子受体)是表皮生长因子受体家族中的受体之一。 HER2的过度表达在25%至35%的患者中测定,患有乳腺癌和一些不同的癌症,如卵巢癌,子宫癌症......由于这种特征,HER2已成为预先的有效分子标记-Diagnosis以及免疫治疗治疗的攻击靶标。目前,基于重组DNA技术产生的HER2具有不同类型的单克隆抗体(MAB),其产生了基于重组DNA技术。这些重组MAbs具有许多益处来诊断和制作在治疗乳腺癌方面更有效。在该研究中,设计了一对引物(Bacer2F / Bacer2R),用于扩增已经移动到克隆载体中的Atther2抗体(Atther2 AB)片段(单链可变片段,SCFV)并通过测序证实。已经构建含有该片段(载体Bacmid / Atther2)的表达载体并将其转染到培养的SF9昆虫细胞中以产生重组杆状病毒(R-BV)。然后将病毒感染蚕板蚕豆和重组Ather2AB(R-Atther2 Ab)成功地表达。通过Western印迹分析证实表达的蛋白质。我们使用Ni-NTA亲和层析获得了R-Ather2AB。我们的结果证实我们接受了95%纯度的纯化的R-Anther2 AB,可用于下一个实验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号